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Background. Treatment for hepatitis C virus (HCV) can lead to sustained virological response (SVR) in over 90% of people.
Subsequent recurrence of HCV, either from late relapse or reinfection, reverses the beneﬁcial effects of SVR.
Methods. A search identiﬁed studies analysing HCV recurrence post-SVR. The recurrence rate for each study was calculated
using events/person years of follow-up (PYFU). Results were pooled using a random-effects model and used to calculate 5-year re-
currence risk. Three patient groups were analysed: (1) Mono-HCV infected “low-risk” patients; (2) Mono-HCV infected “high-risk”
patients (injecting drug users or prisoners); (3) human immunodeﬁciency virus (HIV)/HCV coinfected patients. Recurrence was
deﬁned as conﬁrmed HCV RNA detectability post-SVR.
Results. In the 43 studies of HCV mono-infected “low-risk” patients (n = 7969) the pooled recurrence rate was 1.85/1000 PYFU
(95% conﬁdence interval [CI], .71–3.35; I2 = 73%) leading to a summary 5-year recurrence risk of 0.95% (95% CI, .35%–1.69%). For
the 14 studies of HCVmonoinfected “high-risk” patients (n = 771) the pooled recurrence rate was 22.32/1000 PYFU (95% CI, 13.07–
33.46; I2 = 27%) leading to a summary 5-year risk of 10.67% (95% CI, 6.38%–15.66%). For the 4 studies of HIV/HCV coinfected
patients the pooled recurrence rate was 32.02/1000 PYFU (95% CI, .00–123.49; I2 = 96%) leading to a summary 5-year risk of 15.02%
(95% CI, .00%–48.26%). The higher pooled estimates of recurrence in the high-risk and coinfected cohorts were driven by an increase
in reinfection rather than late relapse.
Conclusions. SVR appears durable in the majority of patients at 5 years post-treatment. The large difference in 5 year event rate
by risk group is driven mainly by an increased reinfection risk.
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Infection with the hepatitis C virus (HCV) is a signiﬁcant public
health concern associated with a high burden of morbidity and
mortality [1, 2]. Recent estimates suggest that worldwide, of the
185 million individuals infected, over 700 000 people die annu-
ally as a result of infection [3, 4].
The attainment of a sustained virological response (SVR),
deﬁned as aviremia 12 or 24 weeks after the completion of an-
tiviral therapy (SVR12 or SVR24), is associated with an im-
proved prognosis compared with patients either untreated or
failing therapy. These beneﬁts include improved histology, re-
duced risk of hepatocellular carcinoma, and improved overall
survival [5, 6].
Despite these beneﬁts, treatment uptake for chronic HCV has
been low due to complexities of treatment and poor success rates.
The availability of new highly efﬁcacious regimens provides the
foundation for marked treatment scale-up; however, high costs
are currently limiting access [7–10].
One challenge to treatment scale-up is the risk of HCV recur-
rence, either as late relapse post-SVR or reinfection following
treatment. HCV recurrence is a particular concern in patients
with ongoing high-risk behaviors, such as injecting drug users
(IDUs), who are more susceptible to reinfection, and also pa-
tients coinfected with human immunodeﬁciency virus (HIV)
who may be at increased risk of relapse due to their immuno-
compromised status [11–15].
A number of studies have been carried out to examine the
durability of treatment-induced SVR in patients with chronic
HCV in a variety of patient populations. Our aim was to sys-
tematically review the existing evidence and undertake meta-
analysis to provide summary estimates of the recurrence rate
by risk group. The secondary aim was to evaluate the contribu-
tion of late relapse and of reinfection to the recurrence rate. This
work ﬁts within the theme one of the PROGRESS framework
for prognosis research (“fundamental prognosis research”)
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and will provide a clearer understanding of HCV recurrence to
inform the provision of antiviral therapy [16].
METHODS
Search Strategy and Inclusion Criteria
The MEDLINE database was searched from 1990 until 1 March
2015 for studies analyzing HCV recurrence post-SVR. A sensi-
tive search string was developed using terms including hepatitis
C, treatment, SVR, recurrence, relapse, and reinfection (Supple-
mentary Appendix). The reference lists of articles were thor-
oughly searched to identify additional articles. Lastly, the
proceedings of the following conferences were search for addi-
tional studies: International Liver Congress (EASL), The Liver
Meeting (AASLD), Conference on Retroviruses and Opportu-
nistic Infections, and the International AIDS Conference.
Studies included were to have enrolled adult patients (aged
≥18) who achieved SVR after antiviral treatment for acute or
chronic HCV. SVR was deﬁned as undetectable HCV RNA
12 or 24 weeks post-treatment. There was no stipulated method
of HCV acquisition or speciﬁc antiviral treatment regimen.
There were no restrictions on study design however all studies
were to have a follow-up longer than 6 months post-SVR. Stud-
ies were excluded if they examined rate of recurrence after spon-
taneous clearance, or if they measured recurrences after the end
of treatment, not allowing for the SVR time period to elapse.
Studies were categorized in to 3 groups: (1) Low-risk popula-
tion, inclusive of studies of mono-HCV infected patients with no
recognized risk factors for reinfection; (2) High-risk population,
inclusive of studies of mono-HCV infected patients with at least 1
identiﬁed risk factor for reinfection; and (3) HIV/HCV coinfec-
tion populations, inclusive of all studies of HIV/HCV coinfected
persons, regardless of the presence or absence of other risk fac-
tors. Risk factors for reinfection were deﬁned as current or former
IDU, imprisonment, and men who have sex with men (MSM).
Studies of liver transplant recipients were excluded.
Quality Assessment
Articles meeting the inclusion criteria were assessed for meth-
odological quality using the Newcastle–Ottawa Scale (NOS).
The assessment was modiﬁed to allocate a maximum of 8 stars,
for quality of selection, comparability, exposure, and outcome of
study participants (Supplementary Appendix). Studies with a
NOS rating ≥6 were considered high-quality.
Data Extraction
The following data were extracted for each study: location, design,
recruitment, patient characteristics, average follow-up time, num-
ber of HCV recurrences, total PYFU, and frequency of HCV
RNA assessment. HCV recurrence was deﬁned as conﬁrmed
HCV RNA detectability post-SVR. Where possible, recurrence
was characterized as either late relapse or as reinfection, with cat-
egorization carried out according to the original study deﬁnitions
and techniques. In all studies using phylogenetic techniques late
relapse was deﬁned as detection of HCV RNA of the same virus
lineage and reinfection as identiﬁcation of a different virus. In the
majority of studies, this classiﬁcation was according to the proto-
col in the original article. In genotyping studies where no criteria
for classiﬁcation were given, the same deﬁnitions were applied by
the authors of the current meta-analysis. In some studies, catego-
rization was done by the study authors without conﬁrmatory
genotyping. In these studies, the decision to classify as late relapse
or reinfection was usually made through consultation with pa-
tients to assess for the presence or absence of risk behaviors
(eg, injecting drug use, unsafe procedures, etc.).
PYFU were accrued from the SVR time-point; in those studies
where follow-up originated at the end-of-treatment, PYFU were
appropriately adjusted. If total PYFU was not explicitly stated, it
was estimated from the average follow-up time; studies in which
PYFU was inestimable were excluded. In the case of study dupli-
cations, the article providing the most comprehensive account of
the study population and longest follow-up period was used.
The literature search, data extraction, and quality assessment
were carried out independently by 2 authors (B. S., J. S.), and
any differences were resolved by consensus.
Data Synthesis
For each study, the incidence rate of HCV recurrence was calcu-
lated as the number of recurrences per 1000 PYFU and was re-
ported with the corresponding 95% Wilson conﬁdence interval
(95% CI). Given the rarity of events, estimates were transformed
using the Freeman-Tukey double arcsine transformation [17, 18].
A pooled estimate for recurrence was then calculated for each of
the three groups separately using a random-effects model [19]. In
addition, meta-analyses of the rate of late relapse and of the rate
of reinfection were carried out including studies providing this
data. The pooled estimates were used to calculate the 5-year
event rate for recurrence, late relapse, and reinfection for each
population. The summary 5-year risk was calculated using 1 –
(1 – pooled incidence rate)5 and as such assumed that the pooled
rate of recurrence was constant over the follow-up duration. For
each calculation, the degree of heterogeneity between studies was
quantitatively assessed using I2 and tau2, where an I2≥ 50% may
indicate substantial heterogeneity and ≥75% is indicative of con-
siderable heterogeneity. The existence of publication bias was
evaluated by observational analysis of funnel plots. All analyses
were conducted using STATA version 13 (StataCorp LP, Texas).
RESULTS
As shown in Figure 1, a total of 1180 references were identiﬁed
and screened for eligibility. Of these, results were available from
59 studies reporting on recurrence post-SVR in a total of 9049
patients. Two studies evaluated two distinct subgroups of
monoinfected and HIV coinfected patients and as such were in-
cluded in 2 analysis groups. Of the studies deemed possibly rel-
evant and screened against inclusion criteria, the main reasons
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for exclusion were the assessment of recurrence rate after spon-
taneous clearance and the lack of an SVR time period after the
end-of-treatment. The study and cohort characteristics are
shown in Table 1. All identiﬁed studies evaluated SVR at 24
weeks post-treatment; no studies eligible for inclusion used
SVR12 as the endpoint for analysis. Frequency of HCV RNA
assessment varied from every 3 months to 1 single assessment
during follow-up. For all 3 risk groups, funnel plots appeared
symmetrical indicating no evidence of bias. Of all studies, 49/
59 (83%) were considered high-quality (NOS score ≥6). The
main biases observed were in determining PYFU and in accept-
ing the authors’ opinion regarding reinfection vs relapse.
Figure 1. Flow diagram of study selection for systematic review of hepatitis C virus (HCV) recurrence in patients achieving a sustained virologic response after treatment for
HCV infection. Low-risk studies include those examining recurrence in general populations and high-risk studies include those studying patients with at least 1 reinfection risk
factor (injecting drug use or prison populations). Human immunodeficiency virus (HIV)/HCV coinfected studies include all those of coinfected participants, regardless of risk
factors. Total studies in the 3 groups does not equal the total number of studies identified as 2 studies examined 2 populations.
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Table 1. Study Characteristics of Included Studies
Study, Year (Ref) Location and Study Design Recruitment and Exclusion Criteria Treatment
Total
With SVR
Mean
Age
%
Male
Frequency of HCV RNA
Testing
NOS
Ratinga
Low risk of reinfection
Howe et al 2015 [20] Europe, US, and Canada; Long-term
FU of RCTs
Genotype-1 with compensated liver disease
enrolled in Phase 2/3 BOC studies
BOC + Peg-IFN + RBV 696 NR NR Every 3 mo for 6 mo, then
6 mo
7 (1)
Koh et al 2013/Hara et al
2014 [21, 22]
US; Long-term FU of clinical
research protocols
Enrolled in clinical research by National Institute
of Diabetes and Digestive and Kidney
Diseases
Peg-IFN or IFN ± RBV 103 56 56 Regularly (freq. NR) 7 (1)
Manns et al 2013 [23] International; Long-term FU of RCTs Enrolled in 2 phase 3 studies; No HBV or HIV
coinfection and no active substance abuse
Peg-IFN ± RBV
IFN ±RBV
366
636
46
43
62
63
Annually (for 5 y) 6 (0)
Giordanino et al 2013 [24] Italy; Prospective cohort Consecutive presentation at hepatology clinics;
treatment-naive with no decompensation
Peg-IFN + RBV 115 46 60 Every 6 mo for 3 y, then
annually
6 (–)
Hotho et al 2013 [25] The Netherlands; Long-term FU of
RCT
RCT enrolling genotype-1, treatment-naïve and
experienced patients
Peg-IFN + RBV +
narlaprevir
19 56 74 6 and 18 mo post-SVR 5 (–)
Ignatova et al 2013 [26] Russia; NR NR Antiviral treatment 208 37 52 NR 5 (0)
Papastergiou et al 2013
[27]
Rhodes, Greece; Prospective
cohort
Consecutive enrolment of treatment-naïve
patients in hepatology unit; No HBV or HIV
coinfection
Peg-IFN + RBV 145 47 60 Annually 7 (1)
Rahman et al 2013 [28] Dhaka, Bangladesh; Prospective
cohort
Enrolment from hospital clinic Peg-IFN + RBV 52 41 78 Annually 5 (0)
Rutter et al 2013 [29] Vienna, Austria; Long-term FU of
clinical research protocols
Enrolment from prospective RCTs and early
access programme
Peg-IFN + RBV +DAA 103 48 67 At least annually 6 (1)
Torres Ibarra et al 2013 [30] Mexico; Retrospective cohort Consecutive enrolment from medical centre Peg-IFN or IFN ± RBV 188 43 46 Every 6 mo 7 (0)
Uyanikoglu et al 2013 [31] Turkey; Retrospective cohort Consecutive enrolment from hospital clinic Peg-IFN or IFN ± RBV 196 46 45 Every 6 mo 7 (0)
Li et al 2012 [32] Chongqing, China; Retrospective
cohort
NR Peg-IFN or IFN ± RBV 146 NR NR NR 5 (0)
Maruoka et al 2012 [33] Chiba, Japan; Retrospective cohort Consecutive enrolment of patients undergoing
liver biopsy at hospital; No HBV or HIV
coinfection
IFN therapy 207 48 66 Every 1–3 mo 7 (–)
Choi et al 2011 [34] Busan, Korea; Retrospective cohort Consecutive enrolment from hospital clinic Peg-IFN + RBV 224 48 58 Every 6 mo 7 (–)
Morisco et al 2011 [35] Italy; Prospective cohort Consecutive enrolment from hospital clinics Peg-IFN or IFN ± RBV 150 48 67 Every 6 mo for 3 y, then
annually
6 (–)
Puig-del-Castillo et al 2011
[36]
Barcelona, Spain; Retrospective
cohort
Consecutive enrolment from hospital clinics Peg-IFN + RBV 80 41 70 Single assessment after 5
y
7 (1)
Trapero-Marugán et al
2011 [37]
Madrid, Spain; Prospective cohort Consecutive enrolment from hospital hepatitis
clinic; No HIV or HBV coinfection and no
alcohol or IDU abuse
Peg-IFN + RBV 153 49 54 Annually (for 5 y) 7 (–)
da Costa Ferreira et al 2010
[38]
São Paulo, Brazil; Retrospective
cohort
Enrolment from hospital hepatitis clinic; No
HBV or HIV coinfection
Peg-IFN or IFN ± RBV 174 46 73 Annually 7 (0)
De Jesús et al 2010 [39] Puerto Rico; Retrospective cohort Enrolment from hospital clinic Peg-IFN or IFN ± RBV 64 54 98 Single assessment 6 (0)
Giannini et al 2010 [40] Genoa, Italy; Prospective cohort Consecutive presentation at hospital hepatitis
unit; No HIV coinfection and no IDU or
alcohol abuse
Peg-IFN + RBV 231 44 60 Every 6 mo 7 (1)
Kim et al 2010 [41] Daejeon, Korea; Retrospective
cohort
Review of medical records from 1 hospital Peg-IFN + RBV 37 NR 81 NR 6 (–)
Lee et al 2010 [42] Seoul, Korea; Prospective cohort Enrolment from hospital clinic Peg-IFN + RBV 68 55 62 NR 6 (0)
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Table 1 continued.
Study, Year (Ref) Location and Study Design Recruitment and Exclusion Criteria Treatment
Total
With SVR
Mean
Age
%
Male
Frequency of HCV RNA
Testing
NOS
Ratinga
Morgan et al 2010 [43] US; Long-term FU of clinical
research protocols
Enrolled in HALT-C trial; patients with advanced
disease and treatment-experience
Peg-IFN + RBV 91 49 76 Single assessment 5 (1)
Sood et al 2010 [44] Ludhiana, India; Prospective cohort Enrolment from hospital clinic; No HBV or HIV
coinfection
Peg-IFN or IFN + RBV 100 41 78 Annually 7 (0)
Swain et al 2010 [45] Europe, US, and Canada; Long-term
FU of RCTs
Enrolled on to multicentre RCTs; No HBV or HIV
coinfection and no alcohol or IDU abuse in
past year
Peg-IFN + RBV
Peg-IFN monotherapy
1077
166
NR
NR
63
60
Annually (for 5 y) 6 (0)
George et al 2009 [46] Madrid, Spain; Prospective cohort NR; No HBV or HIV coinfection Peg-IFN or IFN + RBV 147 49 50 Annually 7 (–)
Hofer et al 2009 [47] Vienna, Austria; Retrospective
cohort
Enrolment from hospital clinic Peg-IFN or IFN ± RBV 251 NR 65 NR 6 (–)
Kim et al 2009 [48] Incheon, Korea; Retrospective
cohort
Enrolment from hospital clinic Peg-IFN or IFN ± RBV 73 47 36 NR 6 (0)
Maylin et al 2008 [49] Clichy, France; Retrospective
cohort
Enrolment from hospital and follow-up in
outpatient clinic
Peg-IFN or IFN ± RBV 344 45 69 Annually 7 (–)
Adamek et al 2007 [50] Poland; NR NR; No HBV or HIV coinfection IFN + RBV 78 43 64 Single assessment 5 (–)
Chavalitdhamrong et al
2006 [51]
Bangkok, Thailand; Retrospective
cohort
Enrolment from hospital hepatitis clinic; No
HBV or HIV coinfection
IFN therapy 171 48 90 Every 6–12 mo 6 (–)
Ciancio et al 2006 [52] Turin, Italy; Long-term FU of RCT Enrolled onto RCT with prior treatment-
experience
Peg-IFN + RBV 97 43 72 Every 6 mo 5 (0)
Desmond et al 2006 [53] Melbourne, Australia; Retrospective
cohort
Enrolment from hospital hepatitis clinic Peg-IFN or IFN ± RBV 147 40 67 Every 6–12 mo 8 (1)
Moreno et al 2006 [54] Oviedo, Spain; Retrospective cohort Consecutive enrolment at hospital clinic Peg-IFN or IFN ± RBV 132 37 64 NR 6 (–)
Yu et al 2005 [55] Kaohsiung, Taiwan; Prospective
cohort
Enrolment from hospital clinic; No HBV
coinfection
Peg-IFN or IFN
therapy
64 44 47 Annually 7 (0)
Khokhar et al 2004 [56] Islamabad, Pakistan; Prospective
cohort
Enrolment from hospital clinic IFN + RBV 57 46 NR Every 6 mo (for 3 y) 8 (0)
Tsuda et al 2004 [57] Japan; Retrospective cohort Consecutive enrolment from hospital clinics IFN therapy 38 51 72 At least every 6 mo 6 (–)
Veldt et al 2004 [58] Europe; Long-term FU of clinical
research protocols
Consecutive enrolment from European centres,
all patients participated in protocolled studies
IFN monotherapy 286 41 59 Every 6 mo 6 (0)
Ponsoda Arlettaz et al
2002 [59]
Montpellier, France; NR NR IFN ±RBV 125 48 NR Every 6 mo 5 (–)
Diago et al 2001 [60] Valencia, Spain; Prospective cohort NR; Prior treatment experienced IFN + RBV 19 NR NR 6 and 18 mo post-SVR 5 (0)
Fontaine et al 2000 [61] Paris, France; NR Enrolment from hepatology unit IFN ± RBV 44 NR 41 Every 6 mo 5 (0)
Marcellin et al 1997 [62] Clichy, France; Prospective cohort
(63% from RCTs)
Consecutive enrolment from clinic; No HBV or
HIV coinfection
IFN monotherapy 75 NR 59 Every 6 mo 7 (0)
Reichard et al 1995 [63] Sweden; Long-term FU of RCT Multicentre enrolment IFN monotherapy 14 50 57 6 (0)
High risk of reinfection (IDUs and prisoners)
Weir et al 2014 [64] Scotland; Retrospective cohort IDUs identified using Scottish HCV and clinical
laboratory data and records
Antiviral treatment 277 NR NR One or two assessments 6 (0)
Ruzic et al 2013 [65] Vojvodina, Serbia; Retrospective-
prospective cohort
IDUs with 1-year abstinence enrolled at
infectious disease clinic
Peg-IFN + RBV 20 30 63 Single assessment after 5-
years follow-up
6 (–)
Hilsden et al 2013 [66] Alberta and Vancouver, Canada;
Long-term FU of RCT
Recent IDU or crack cocaine use (within 3 mo);
enrolled in to community-based RCT to
received treatment or delayed treatment; No
HBV or HIV coinfection
Peg-IFN + RBV 23 41 91 NR 7 (0)
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Table 1 continued.
Study, Year (Ref) Location and Study Design Recruitment and Exclusion Criteria Treatment
Total
With SVR
Mean
Age
%
Male
Frequency of HCV RNA
Testing
NOS
Ratinga
Edlin et al 2013 [67] New York, US; NR Active IDU enrolled at community based
needle exchange program; enrolled both
acute and chronic HCV
Peg-IFN + RBV 15 36 74 NR 5 (0)
Conway et al 2013 [68] Vancouver, Canada; Prospective
cohort
IDUs treated within multidisciplinary program;
enrolled both acute and chronic HCV
Peg-IFN + RBV or
DAA regimen
70 53 96 At least every 6 mo 8 (1)
Deshaies et al 2013 [69] Quebec City, Canada; Prospective
cohort
Active IDU enrolled in community setting
(TACTIC project)
Antiviral treatment 20 39 60 5 (0)
Grady et al 2012 [70] Amsterdam, The Netherlands;
Prospective cohort
IDUs enrolled in Amsterdam Cohort Studies of
drug users
Peg-IFN + RBV 42 51 74 Every 6–12 mo 7 (0)
Manolakopouos et al 2012
[71]
Athens, Greece; Retrospective
cohort
Past and current IDUs enrolled in
multidisciplinary supervised program at three
liver units
Antiviral treatment 61 38 80 Single assessment (mean
2 y post-SVR)
6 (1)
Grebely et al 2010 [72] Vancouver, Canada; Prospective
cohort
Enrolment at addiction clinics; 54% IDU in
previous 6 mo (100% ever IDU); enrolment
at community clinics providing addiction
services
IFN or Peg-IFN + RBV 35 44 96 Annually 8 (1)
Currie et al 2008 [73] San Francisco, US; Prospective
cohort
IDUs part of a larger study; advertisements for
enrolment in hospitals, liver and methadone
clinics etc.
Antiviral treatment 9 46 89 Every 6 mo 8 (0)
Backmund et al 2004 [74] Munich, Germany; Prospective
cohort
Opiate-dependent IDUs; enrolled during
detoxification treatment
IFN ± RBV 18 32 61 Annually 8 (1)
Dalgard et al 2002 [75] Oslo, Norway; Prospective long-
term FU of RCT
IDU as route of transmission; abstinent for ≥6
mo
IFN ±RBV 27 30 67 NR 6 (1)
Marco et al 2013 [76] Catalonia, Spain; Retrospective
cohort
Prisoners treated in routine clinical practice;
20% with risk factor for reinfection
Peg-IFN + RBV 101 33 97 Annually 8 (1)
Bate et al 2010 [77] Adelaide, Australia; Retrospective
cohort
Incarcerated for entire planned duration of
therapy; 55% past/present IDU
IFN or Peg-IFN ± RBV 53 34 95 NR 7 (1)
HIV/HCV coinfected
Martin et al 2013 [78] London, UK; Retrospective cohort HIV-positive MSM enrolled at HIV clinic;
patients excluded if primary mode of
transmission was via contaminated blood
products or IDU; enrolled both acute and
chronic HCV
Antiviral treatment
(91% on ART)
114 41 100 NR 6 (0)
Marco et al 2013 [76] Catalonia, Spain; Retrospective
cohort
Prisoners treated in routine clinical practice;
20% with risk factor for reinfection
Peg-IFN + RBV (100%
on ART)
18 33 98 Annually 7 (1)
Swain et al 2010 [45] Europe, US, and Canada; Long-term
FU of RCTs
HIV-positive enrolled into RCT at different
centres
Peg-IFN ± RBV 100 NR 82 Annually (for 5 y) 6 (0)
Soriano et al 2004 [79] Spain; Retrospective FU of RCTs HIV-positive enrolled on 4 different RCTs; no
HBV coinfection or active drug or alcohol
abuse
Peg-IFN + RBV (53%
on ART)
77 34 68 Regularly (freq. NR) 7 (–)
Abbreviations: ART, antiretroviral therapy; BOC, boceprevir; DAA, direct acting antiviral; FU, follow-up; HALT-C, hepatitis C antiviral long-term treatment against cirrhosis; HBV, hepatitis B virus; HCV, hepatitis C virus; HIV, human immunodeficiency virus; IDU,
injecting drug user; IFN, interferon; MSM, men who have sex with men; NOS, Newcastle-Ottawa Scale; NR, not reported; Peg-IFN, pegylated-interferon; RBV, ribavirin; RCT, randomized controlled trial; SVR, sustained virological response.
a NOS score is score out of 8; score in brackets is the score for the quality of categorization of recurrence as either late relapse or reinfection, where 1 indicates distinction was based on genotyping, 0 indicates distinction was by author/clinician discretion or no
distinction was made, and – indicates that no recurrences were observed.
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Low-risk Population
Forty-three articles were found evaluating the risk of recurrence
in 7969 low-risk patients. Of these, 29 were prospective or ret-
rospective cohorts, and 10 follow-up patients enrolled in ran-
domized clinical trials (RCTs) or research protocols; study
type was not recorded in 4 studies. All studies were carried
out in patients with chronic HCV. In 39 studies, patients were
treated with peg-IFN or IFN, either in combination with riba-
virin or as monotherapy. In 3 studies, treatment consisted of
peg-IFN, ribavirin, and a DAA (boceprevir n = 1, narlaprevir
n = 1, unspeciﬁed n = 1); treatment regimen was not speciﬁed
in the ﬁnal study. The mean of the average follow-up post-
SVR was 3.9 years (range, 1.0–8.7 years). Of the 28 studies
with at least 1 recurrence, 11 used genotyping or sequencing
to determine recurrence type, 5 relied on author judgment/ter-
minology, and 12 did not classify the recurrence.
Overall, 108/7969 experienced HCV recurrence with individ-
ual study recurrence rates varying from 0.00/1000 PYFU to
70.18/1000 PYFU (Table 2). Following random effects meta-
analysis, the pooled estimate for the recurrence rate was 1.85/
1000 PYFU (95% CI, .71–3.35; Table 3); however, a high level
of heterogeneity was observed (I2 = 73.0%). Based on this
pooled estimate, the corresponding 5-year recurrence risk was
0.95% (95% CI, .35%–1.69%; Figure 2).
The pooled estimate was 0.82/1000 PYFU (95% CI, .08–2.05)
for late relapse, and 0.00/1000 PYFU (95% CI, .00–.00) for re-
infection (Table 2). These estimates led to 5-year late relapse
and reinfection rates of 0.40% (95% CI, .35%–1.05%) and
0.00% (95% CI, .00%–.00%), respectively (Figure 2).
High-risk Population
In total, 14 articles were found that assessed HCV recurrence in
high-risk patients. Of these studies, 12 evaluated the risk in
IDUs (n = 617) and 2 in prisoners (n = 154). In sum, 10 of 12
IDU studies were cohorts, and 2 were the long-term follow-up
from RCTs. Both studies of prisoners were retrospective cohorts
of patients receiving treatment while under detention. Twelve of
the studies were conducted in patients with chronic HCV exclu-
sively, and 2 studies enrolled patients with acute and chronic
HCV. Patients received peg-IFN or IFN with or without ribavi-
rin in 9 studies and either peg-IFN plus ribavirin or a DAA reg-
imen in 1 study; 4 studies did not specify the antiviral regimen.
The average of the mean follow-up post-SVR was 2.8 years
(range 1.4–4.9 years). Overall, 9/13 studies with at least 1 recur-
rence used genotyping to classify the recurrence type.
In total, 42 recurrences were observed in a total of 771 pa-
tients. The recurrence rate varied from 0.00/1000 PYFU to
63.09/1000 PYFU in each study (Table 2); the pooled estimate
for recurrence was 22.32/1000 PYFU (95% CI, 13.07–33.46)
and a low level of heterogeneity was observed (I2 = 27.3%;
Table 3). As shown in Figure 2, this estimate led to a 5-year
recurrence rate of 10.67% (95% CI, 6.38%–15.66%) and was
driven mainly by reinfection (19.06/1000 PYFU, 95% CI,
11.42–28.16) rather than late relapse.
HIV/HCV Coinfected Population
Of the 4 studies identiﬁed assessing recurrence in the HIV/HCV
coinfected patients, 1 was carried out exclusively in MSM, 1 en-
rolled incarcerated patients only, and the remaining 2 recruited
a mixed population. Two studies were cohort studies (n = 132)
and two (n = 177) were long-term follow-up of RCTs. Three of
the studies enrolled patients with chronic HCV, and the re-
maining study enrolled patients with both acute and chronic
disease. Patients received peg-IFN or IFN with or without riba-
virin in 3 studies; 1 study did not specify the regimen. In sum, 3
of the 4 studies reported the proportion of patients receiving an-
tiretroviral therapy for HIV infection. In total, 78% of patients
were receiving treatment ranging from 53% to 100% in the 3
studies. Of the 4 studies, 2 excluded patients with active IDU,
and 2 enrolled patients with either a history of IDU or drug
use during or after treatment. The average of the mean fol-
low-up post-SVR was 3.3 years (1.6–4.3 years). One of the 3
studies reporting at least 1 recurrence used genotyping tech-
niques to classify the recurrence.
Overall, 31/309 patients experienced a recurrence for a pooled
recurrence rate of 32.02/1000 PYFU (95%CI, .00–123.49; Table 3);
however, a substantial level of heterogeneity was observed and in-
dividual study recurrence rates varied from 0.00 to 133.93/1000
PYFU. The pooled rate led to a 5-year recurrence rate of 15.02%
(95% CI, .00%–48.26%; Figure 2).
By recurrence type, the pooled estimate for late relapse was
0.00/1000 PYFU (95% CI, .00–.03) and for reinfection it was
32.02/1000 PYFU (95% CI, .00–123.49), leading to a 5-year
risk of 0.0% (95% CI, .0%–.01%) and 15.02% (95% CI, .00%–
48.26%), respectively. The uncertainties of the reinfection esti-
mate are reﬂected by the wide 95% CI and the high level of
heterogeneity observed.
To attempt to understand the heterogeneity, an analysis of
RCTs compared with unselected patient cohorts was conduct-
ed. The pooled estimate of recurrence was signiﬁcantly lower for
patients followed-up after RCTs, leading to a signiﬁcantly lower
5-year recurrence rate compared to the unselected cohorts
(0.46% [95% CI, .00–2.65] vs 45.86% [95% CI, 32.86–58.27]).
These data however should be interpreted with caution given
the small number of studies available for evaluation (2 studies
in each group) and the substantial between study heterogeneity
observed (I2 = 98.7%).
DISCUSSION
Achieving SVR substantially reduces the risk of hepatocellular
carcinoma, cirrhosis, and mortality, however these beneﬁts are
lost following recurrent infection [80]. In this meta-analysis,
the risk of HCV recurrence after treatment-induced SVR was
found to be 1.85/1000 PYFU in the low-risk group and rose to
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Table 2. Hepatitis C Virus Recurrences and Rate of Recurrence in Included Studies
Study
Number
With SVR
Avg. Follow-up
Post-SVR
(Total PYFU
Post-SVR) Method
Recurrences
Recurrence Rate per
1000 PYFU (95% CI)
Late Relapse
(Confirmed)a
Reinfection
(Confirmed)b Totalc
Low-risk studies
Howe et al 2015 696 3.4 (2227.2) Sequencing 3 (0) 1 (1) 4 1.80 (.70–4.61)
Koh et al 2014 103 7.5 (772.5) Genotyping 3 (3) 0 3 3.88 (1.32–11.36)
Manns et al 2013 Peg-IFN ± RBV 366 4.1 (1517.1) Genotyping 3 (0) 2 (2) 5 3.30 (1.41–7.69)
IFN ± RBV 636 4.94 (3141.8) 6 (0) 0 6 1.91 (.88–4.16)
Giordanino et al 2013 115 8.7 (1000.5) – 0 0 0 0.00 (.00–3.82)
Hotho et al 2013 19 1.8 (34.2) – 0 0 0 0.00 (.00–100.98)
Ignatova et al 2013 208 4.7 (972.4) None – – 3 3.09 (1.05–9.03)
Papastergiou et al 2013 145 5.7 (820.0) Genotyping and
risk factors
1 (0) 1 (1) 2 2.44 (.67–8.85)
Rahman et al 2013 52 4.2 (216.0) Terminology 4 (0) 0 4 18.52 (7.22–46.64)
Rutter et al 2013 103 1.8 (180.3) Genotyping and
sequencing
2 (2) 0 2 11.09 (3.05–39.54)
Torres Ibarra et al 2013 188 5.8 (1081.0) None – – 3 2.78 (.94–8.13)
Uyanikoglu et al 2013 196 2.8 (547.2) Terminology 2 (0) 0 2 3.65 (1.00–13.23)
Li et al 2012 146 1.5 (219.0) None – – 7 31.96 (15.57–64.50)
Maruoka et al 2012 207 7.5 (1552.5) – 0 0 0 0.00 (.00–2.47)
Choi et al 2011 224 1.5 (336.0) – 0 0 0 0.00 (.00–11.30)
Morisco et al 2011 150 8.6 (1290.0) – 0 0 0 0.00 (.00–2.97)
Puig-del-Castillo et al 2011 80 5.0 (400.0) Genotyping 1 (0) 0 1 2.50 (.44–14.02)
Trapero-Marugán et al 2011 153 6.3 (969.0) Genotyping 0 0 0 0.00 (.00–3.95)
da Costa Ferreira et al 2010 174 3.9 (681.5) None – – 1 1.47 (.26–8.26)
De Jesús et al 2010 64 2.6 (164.8) Risk factors 1 (0) 0 1 6.07 (1.07–33.57)
Giannini et al 2010 231 3.1 (725.7) Genotyping and
risk factors
2 (2) 0 2 2.76 (.76–9.99)
Kim et al 2010 37 1.0 (37.0) – 0 0 0 0.00 (.00–94.06)
Lee et al 2010 68 1.6 (108.8) None – – 5 45.96 (19.79–103.09)
Morgan et al 2010 91 6.6 (596.1) Genotyping 1 (0) 0 1 1.68 (.30–9.44)
Sood et al 2010 100 3.0 (301.0) None – – 8 26.58 (13.53–51.56)
Swain et al 2010 Peg-IFN + RBV 1077 3.8 (4079.1) None – – 9 2.21 (1.16–4.19)
Peg-IFN mono 166 4.6 (760.5) – – 2 2.63 (.72–9.54)
George et al 2009 147 4.6 (673.3) – 0 0 0 0.00 (.00–5.67)
Hofer et al 2009 251 4.2 (1054.2) – 0 0 0 0.00 (.00–3.63)
Kim et al 2009 73 1.4 (103.1) None – – 1 9.70 (1.71–52.91)
Maylin et al 2008 344 3.3 (1258.5) – 0 0 0 0.00 (.00–3.04)
Adamek et al 2007 78 1.8 (142.4) – 0 0 0 0.00 (.00–26.27)
Chavalitdhamrong et al 2006 171 2.4 (418.6) – 0 0 0 0.00 (.00–9.09)
Ciancio et al 2006 97 7.2 (695.2) Terminology 11 (0) 0 11 15.82 (8.86–28.11)
Desmond et al 2006 147 2.3 (338.1) Genotyping and
risk factors
1 (0) 0 1 2.96 (.52–16.56)
Moreno et al 2006 132 3.0 (396.0) – 0 0 0 0.00 (.00–9.61)
Yu et al 2005 64 6.8 (435.8) Genotyping – – 1 2.29 (.41–12.88)
Khokhar et al 2004 57 3.0 (171.0) None – – 5 29.24 (12.55–66.61)
Tsuda et al 2004 38 5.7 (216.6) Genotyping 0 0 0 0.00 (.00–17.43)
Veldt et al 2004 286 4.4 (1225.5) Terminology 12 (0) 0 12 9.79 (5.61–17.04)
Ponsoda Arlettaz et al 2002 125 1.2 (145.8) – 0 0 0 0.00 (.00–25.67)
Diago et al 2001 19 1.5 (28.5) None – – 2 70.18 (19.46–223.00)
Fontaine et al 2000 44 1.2 (53.9) None – – 1 18.55 (3.28–97.88)
Marcellin et al 1997 75 3.5 (250.1) None – – 1 4.00 (.71–22.30)
Reichard et al 1999 26 4.9 (127.4) Genotyping 2 (0) 0 2 15.70 (4.32–55.43)
High-risk studies
Weir et al 2014 277 4.5 (410.0) Terminology 0 7 (0) 7 17.07 (8.29–34.82)
Ruzic et al 2013 20 5 (100.0) – 0 0 0 0.00 (.00–36.99)
Hilsden et al 2013 23 1.8 (35.5) Risk factors 0 1 (0) 1 28.17 (4.99–143.49)
Edlin et al 2013 15 NR (45.1) Terminology 0 1 (0) 1 22.17 (3.92–115.43)
Conway et al 2013 70 2.0 (138.6) Genotyping 0 4 (4) 4 28.86 (11.28–71.85)
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22.32 and 32.02/1000 PYFU in the high-risk and HIV/HCV co-
infection populations, respectively. These incidence rates led to
estimated 5-year recurrence rates of 0.95%, 10.67%, and 15.02%
in the low-risk, high-risk, and coinfection groups, respectively.
Thus, despite higher recurrence rates in those with identiﬁed on-
going risk behaviors and/or HIV infection, SVR is durable, and
the great majority of patients have SVR at 5 years post-treatment.
The current analysis suggests that the greater recurrence risk
in the high-risk and HIV coinfected populations is driven by an
increased likelihood of reinfection, highlighting the need for
prevention campaigns targeted at individuals who continue to
place themselves at high-risk of HCV re-exposure. According
to the inclusion criteria, the meta-analysis evaluated the risk
of recurrence post-treatment. Consequently, studies evaluating
spontaneous cleared were excluded [81–86]. The data from
these studies support the notion that the risk of recurrence is
driven by reinfection in those with high-risk behaviors [87, 88].
Included studies reported contradictory results about the risk
of HCV recurrence among patients with HIV. There remains a
question as to whether higher recurrence rates in HIV patients
are a consequence of HIV and related immune suppression or
to the presence of risk behaviors associated with HCV acquisi-
tion. Given that RCTs tend to have more restricted inclusion cri-
teria than open cohorts, we compared recurrence between the 2
types of study. Although the number of studies was low, evidence
from RCTs suggested a signiﬁcantly lower recurrence rate than
data from open cohorts, supporting the notion that reinfection
in these patient groups, rather than an increased propensity to
relapse, is the main driver to recurrence [45, 76, 78, 79].
It is important to highlight that the majority of studies in-
cluded analyzed recurrence after treatment with interferon-
based therapies. The use of such regimens is decreasing in
favor of interferon-free regimens, and although there is no evi-
dence to support the notion that recurrence rates may differ
with new treatments, it is possible that this will be the case, par-
ticularly if the consequences of reinfection are perceived to be
low. Thus, collecting prospective data on recurrence rates after
treatment with newer therapies is important.
There are a number of limitations to the present study. First,
it is likely that a number of spontaneously clearing recurrent in-
fections were missed, leading to an underestimate of recurrence.
Evidence indicates that the probability of spontaneously clear-
ing recurrent infection is high, and the duration of spontane-
ously clearing infection is about one month [89]. Thus, HCV
RNA assessment at intervals of 6–12 months, as was the case
in the majority of studies, is unlikely to capture all recurrences.
Second, the analysis was limited by the detection and sequenc-
ing methods utilized in the original studies. Evidence from
more sensitive detection methods indicates that long-term per-
sistence of low levels of HCV RNA is possible [90, 91]. While
the clinical signiﬁcance is unclear, it suggests that some patients
thought to have achieved SVR may still harbor the HCV.
Table 2 continued.
Study
Number
With SVR
Avg. Follow-up
Post-SVR
(Total PYFU
Post-SVR) Method
Recurrences
Recurrence Rate per
1000 PYFU (95% CI)
Late Relapse
(Confirmed)a
Reinfection
(Confirmed)b Totalc
Deshaies et al 2013 20 1.6 (31.7) Genotyping 0 2 (1) 2 63.09 (17.48–203.15)
Grady et al 2012 42 2.0 (110.6) Sequencing 0 1 (0) 1 9.04 (1.60–49.45)
Manolakopouos et al 2012 61 2.0 (122.0) Genotyping 0 5 (4) 5 40.98 (17.63–92.36)
Grebely et al 2010 35 2.0 (62.5) Genotyping and
risk factors
0 2 (1) 2 32.00 (8.82–109.38)
Currie et al 2008 9 3.6 (38.0) Terminology 0 1 (0) 1 26.32 (4.66–134.95)
Backmund et al 2004 18 2.8 (48.8) Genotyping 0 1 (1) 2 40.98 (11.31–137.65)
Dalgard et al 2002 27 4.9 (118.0) Genotyping 0 1 (1) 1 8.47 (1.50–46.45)
Marco et al 2013 101 1.4 (148.5) Genotyping and
risk factors
0 6 (5) 6 40.40 (18.65–85.34)
Bate et al 2010 53 3.4 (180.4) Genotyping 5 (5) 4 (4) 9 49.89 (26.47–92.08)
HIV/HCV coinfected
Martin et al 2013 114 1.6 (224.3) Terminology 0 27 (0) 27 120.37 (84.06–169.47)
Marco et al 2013 18 NR (22.4) Genotyping and
risk factors
0 3 (2) 3 133.93 (46.62–328.41)
Swain et al 2010 100 4.0 (398.3) Risk factors 0 1 1 2.51 (.44–14.08)
Soriano et al 2004 77 4.3 (333.7) – 0 0 0 0.00 (.00–11.38)
Entries marked with a dash gave no indication whether the recurrence was a late relapse or a reinfection.
Number of late relapses plus number of reinfections does not always equal the total number of cases if the description of certain cases was not provided.
Abbreviations: CI, confidence interval; HCV, hepatitis C virus; HIV, human immunodeficiency virus; NR, not reported; Peg-IFN, pegylated-interferon; PYFU, person-years of follow-up;
RBV, ribavirin; SVR, sustained virologic response.
a Number of suspected late relapses (no. confirmed by genotyping or sequencing).
b Number of suspected reinfections (no. confirmed by genotyping or sequencing).
c Total number of late relapses and reinfections.
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The use of insensitive sequencing methods has particular im-
plications for the late relapse/reinfection subanalysis. Recent ev-
idence with more sensitive deep sequencing techniques suggests
that a number of reinfections may be wrongly classiﬁed and are
actually the emergence of preexisting resistant minority variants
rather than reinfection [92]. Despite this, previous evidence
Table 3. Meta-analysis of Recurrence
Studies Subgroup No. of Studies
Pooled Estimate of Recurrence/1000
PYFU (95% CI)
Heterogeneity
(I2, P Value)
Low-risk
All studies All 43 (45)a 1.85 (.71–3.35) 73.0%; .0039
Sensitivity analysis High-quality (NOS ≥6) 33 (35)a 1.54 (.56–2.85) 69.3%; .0028
Meta-analysis subgroups Late relapse 31 (32)b 0.82 (.08–2.05) 67.3%; .0028
Reinfection 31 (32)b 0.00 (.00–.00) 0.0%; .0000
High-risk
All studies All 14 22.32 (13.07–33.46) 27.3%; .0035
Sensitivity analysis High-quality (NOS ≥6) 12 22.03 (12.50–33.65) 32.0%; .0039
Meta-analysis subgroups Late relapse 14 0.00 (.00–1.72) 0.0%; .0000
Reinfection 14 19.06 (11.42–28.16) 10.5%; .0011
All IDU studies 12 16.99 (8.61–27.41) 13.8%; .0017
All prisoner studies 2 45.48 (24.95–71.32) 92.2%; –
HIV/HCV coinfected
All studies All 4 32.02 (.00–123.49) 96.0%; .1095
Sensitivity analysis High-quality (NOS ≥6) 4 32.02 (.00–123.49) 96.0%; .1095
Meta-analysis subgroups Recurrence in cohorts 2 115.47 (76.58–160.38) 98.7%; –
Recurrence in RCTs 2 0.91 (.005.35) 98.7%; –
Late relapse 4 0.00 (.00–.03) 0.0%; .0000
Reinfection 4 32.02 (.00–123.49) 96.0%; .1095
Forest Plots of recurrence rates can be found in the Supplementary Appendix.
Abbreviations: CI, confidence interval; HCV, hepatitis C virus; HIV, human immunodeficiency virus; IDU, injecting drug user; NOS, Newcastle–Ottawa Scale; PYFU, person-years of follow-up;
RCT, followed-up from randomized controlled trial.
a Two studies included 2 different treatment groups.
b One study included 2 different treatment groups.
Figure 2. Summary 5-year risk (95% confidence interval) of recurrence post-sustained virological response (SVR), by risk group. Presented are the pooled estimates for the
5-year risk of recurrence after achieving an SVR. Also shown are the number of studies that were included to derive each estimate. Abbreviations: HCV, hepatitis C virus;
HIV, human immunodeficiency virus.
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corroborates this analysis showing that late relapse following
SVR is rare, occurring in <1% of mono- and coinfected individ-
uals [45]. Furthermore, many recurrent cases have good out-
comes, in terms of high spontaneous and treatment-induced
clearance rates, supporting the mechanism of reinfection with
novel susceptible virus, rather than the emergence of resistant
low-level variants [93]. The distinction between late relapse
and reinfection is particularly important when the epidemio-
logical differences between risk groups are considered. In
some populations, epidemics are concentrated, limiting genetic
diversity such that reinfection will likely be with a highly similar
strain, and thus will require better techniques to distinguish late
relapse from reinfection [94].
In those studies not utilizing genotyping methods, bias may
have been introduced by the tendency of study authors to clas-
sify recurrent infection as late relapse vs reinfection. Indeed, the
late relapse rate was highest in the low risk group, suggesting
recurrences were more likely attributed to late relapse over rein-
fection, possibly overestimating the relapse rate in this popula-
tion. Similarly, in high-risk groups, relapse may have been
underestimated by the tendency to classify recurrence as rein-
fection when uncertain. Finally, the estimates of late relapse
and reinfection may have been biased by the availability of stud-
ies for inclusion in these analyses. Studies not classifying recur-
rence were excluded meaning that zero event studies were
overrepresented in calculations, possibly leading to an underes-
timate of the true relapse and reinfection rates.
Despite the limitations, the results of the analysis will be
helpful to inform treatment scale-up and modeling of strategies,
which prioritize different groups for therapy with the ultimate
goal of disease eradication. Although the probability of late re-
lapse is low, reinfection in high-risk groups such as IDUs, pris-
oners, and HIV-positive MSM present both a challenge and an
opportunity for epidemic control. As such, strategies to mini-
mize the risk of reinfection in high-risk groups need to be inten-
siﬁed in parallel to introduction of interferon-free regimens in
order to curtail onward transmission. The current analysis
highlights the notion that estimates from RCTs may underesti-
mate recurrence and emphasizes the need for real-life analyses
and an updated analysis once the results of long-term interfer-
on-free studies are available.
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